Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications

World Journal of Orthopedics

Volumn 5, Issue 4, 2014, Pages 516-536

  Magyari, Lili ^a,b   Varszegi, Dalma ^b   Kovesdi, Erzsebet ^a,b   Sarlos, Patricia ^a   Farago, Bernadett ^c   Javorhazy, Andras ^b   Sumegi, Katalin ^a,b   Banfai, Zsolt ^a,b   Melegh, Bela ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Immunologic targets; Interleukins; Polymorphisms; Rheumatoid arthritis; Therapy

Indexed keywords

EID: 84906076440     PISSN: None     EISSN: 22185836     Source Type: Journal    
DOI: 10.5312/wjo.v5.i4.516     Document Type: Article

References (195)

1. Kiss CG, Lövei C, Sütö G, Varjú C, Nagy Z, Füzesi Z, Illés T, Czirják L. Prevalence of rheumatoid arthritis in the South-Transdanubian region of Hungary based on a representative survey of 10,000 inhabitants. J Rheumatol 2005; 32: 1688-1690 [PMID: 16142861]
2. Worthington J. Investigating the genetic basis of susceptibility to rheumatoid arthritis. J Autoimmun 2005; 25 Suppl: 16-20 [PMID: 16257177 DOI: 10.1016/j.jaut.2005.09.011]
3. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911 [PMID: 11567728 DOI: 10.1016/S0140-6736(01)06075-5]
4. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34 [PMID: 8250453]
5. Järvinen P, Aho K. Twin studies in rheumatic diseases. Semin Arthritis Rheum 1994; 24: 19-28 [PMID: 7985034 DOI: 10.1016/0049-0172(94)90096-5]
6. Scutellari PN, Orzincolo C. Rheumatoid arthritis: sequences. Eur J Radiol 1998; 27 Suppl 1: S31-S38 [PMID: 9652499]
7. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701 [PMID: 16508929 DOI: 10.1002/art.21675]
8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-1588 [PMID: 20699241 DOI: 10.1136/ard.2010.138461]
9. Balsa A, Cabezón A, Orozco G, Cobo T, Miranda-Carus E, López-Nevot MA, Vicario JL, Martín-Mola E, Martín J, Pascual-Salcedo D. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther 2010; 12: R62 [PMID: 20370905 DOI: 10.1186/ar2975]
10. Chaiamnuay S, Bridges SL. The role of B cells and autoantibodies in rheumatoid arthritis. Pathophysiology 2005; 12: 203-216 [PMID: 16102949 DOI: 10.1016/j.pathophys.2005.07.007]
11. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001; 44: 2255-2262 [PMID: 11665966]
12. Harris ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-1289 [PMID: 2271017 DOI: 10.1056/NEJM199005033221805]
13. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108 [PMID: 20870100 DOI: 10.1016/S0140-6736(10)60826-4]
14. Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 339-347 [PMID: 12571842 DOI: 10.1002/art.10814]
15. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005; 44: 1414-1421 [PMID: 16030080 DOI: 10.1093/rheumatology/kei031]
16. Czirják L, Kiss CG, Lövei C, Süto G, Varjú C, Füzesi Z, Illés T, Nagy Z. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005; 23: 801-808 [PMID: 16396698]
17. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, Breedveld FC, Toes RE, Huizinga TW. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366-371 [PMID: 16014670 DOI: 10.1136/ard.2005.041079]
18. Klareskog L, Padyukov L, Rönnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006; 18: 650-655 [PMID: 17010589 DOI: 10.1016/j.coi.2006.06.004]
19. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006; 163: 521-528 [PMID: 16513876 DOI: 10.1176/appi.ajp.163.3.521]
20. Mors O, Mortensen PB, Ewald H. A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophr Res 1999; 40: 67-74 [PMID: 10541009]
21. Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect. Hum Immunol 2003; 64: 930-935 [PMID: 14522089]
22. Tamiya G, Shinya M, Imanishi T, Ikuta T, Makino S, Okamoto K, Furugaki K, Matsumoto T, Mano S, Ando S, Nozaki Y, Yukawa W, Nakashige R, Yamaguchi D, Ishibashi H, Yonekura M, Nakami Y, Takayama S, Endo T, Saruwatari T, Yagura M, Yoshikawa Y, Fujimoto K, Oka A, Chiku S, Linsen SE, Giphart MJ, Kulski JK, Fukazawa T, Hashimoto H, Kimura M, Hoshina Y, Suzuki Y, Hotta T, Mochida J, Minezaki T, Komai K, Shiozawa S, Taniguchi A, Yamanaka H, Kamatani N, Gojobori T, Bahram S, Inoko H. Whole genome association study of rheumatoid arthritis using 27 039 microsatellites. Hum Mol Genet 2005; 14: 2305-2321 [PMID: 16000323 DOI: 10.1093/hmg/ddi234]
23. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D, Wilson AG, Marinou I, Morgan A, Emery P, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Worthington J. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet 2008; 17: 2274-2279 [PMID: 18434327 DOI: 10.1093/hmg/ddn128]
24. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TR, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PL, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth BP, Wijmenga C, Karlson EW, Toes RE, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-514 [PMID: 20453842 DOI: 10.1038/ng.582]
25. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA. Interleukins, from 1 to 37, and interferon-?: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127: 701-721.e1-70 [PMID: 21377040 DOI: 10.1016/j.jaci.2010.11.050]
26. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732 [PMID: 21304099 DOI: 10.1182/blood-2010-07-273417]
27. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 Suppl 2: ii11-ii16 [PMID: 12817090 DOI: 10.1093/rheumatology/keg32742/suppl_2/ii11]
28. Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 Suppl 2: ii3-10 [DOI: 10.1093/rheumatology/keg32642/suppl_2/ii3]
29. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59 Suppl 1: i60-i64 [PMID: 11053091 DOI: 10.1136/ard.59.suppl_1.i60]
30. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147 [PMID: 8630372]
31. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1: 450 [PMID: 1301918 DOI: 10.1093/hmg/1.6.450]
32. Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402 [PMID: 1353022 DOI: 10.1111/j.1365-2362.1992.tb01480.x]
33. Cox A, Camp NJ, Cannings C, di Giovine FS, Dale M, Worthington J, John S, Ollier WE, Silman AJ, Duff GW. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8: 1707-1713 [PMID: 10441334 DOI: 10.1093/hmg/8.9.1707]
34. Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H. Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 643-648 [PMID: 17207379]
35. Harrison P, Pointon JJ, Chapman K, Roddam A, Wordsworth BP. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1768-1770 [PMID: 18838388 DOI: 10.1093/rheumatology/ken374]
36. Lubbe S, Tikly M, van der Merwe L, Hodkinson B, Ramsay M. Interleukin-1 receptor antagonist gene polymorphisms are associated with disease severity in Black South Africans with rheumatoid arthritis. Joint Bone Spine 2008; 75: 422-425 [PMID: 18468936 DOI: 10.1016/j.jbspin.2007.09.015]
37. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. J Rheumatol 2002; 29: 212-219 [PMID: 11838837]
38. Huang CM, Tsai FJ, Wu JY, Wu MC. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 225-228 [PMID: 11578018]
39. Grover S, Tandon S, Misra R, Aggarwal A. Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India. Indian J Med Res 2006; 123: 815-820 [PMID: 16885604]
40. Allam I, Djidjik R, Ouikhlef N, Louahchi S, Raaf N, Behaz N, Abdessemed A, Khaldoun N, Tahiat A, Bayou M, Ladjouze-Rezig A, Ghaffor M. Interleukin-1 and the interleukin-1 receptor antagonist gene polymorphisms study in patients with rheumatoid arthritis. Pathol Biol (Paris) 2013; 61: 264-268 [PMID: 23849770 DOI: 10.1016/j.patbio.2013.05.005]
41. Lee YH, Ji JD, Song GG. Association between interleukin 1 polymorphisms and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol 2009; 36: 12-15 [PMID: 19004046 DOI: 10.3899/jrheum.080450]
42. You CG, Li JF, Xie XD, Zhu Y, Li PQ, Chen YR. Association of interleukin-1 genetic polymorphisms with the risk of rheumatoid arthritis in Chinese population. Clin Chem Lab Med 2007; 45: 968-971 [PMID: 17867984 DOI: 10.1515/CCLM.2007.156]
43. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38 [PMID: 18613828 DOI: 10.1111/j.1600-065X.2008.00624.x]
44. Chen S, Jiang F, Ren J, Liu J, Meng W. Association of IL-18 polymorphisms with rheumatoid arthritis and systemic lupus erythematosus in Asian populations: a meta-analysis. BMC Med Genet 2012; 13: 107 [PMID: 23153245 DOI: 10.1186/1471-2350-13-107]
45. Ji JD, Lee WJ. Interleukin-18 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Gene 2013; 523: 27-32 [PMID: 23587914 DOI: 10.1016/j.gene.2013.03.132]
46. Hashaad NI, El-Din MS, Moustafa EF, Abo Elazem AA. Interleukin-18 promoter polymorphisms in Egyptian patients with rheumatoid arthritis. Egypt J Immunol 2012; 19: 13-24 [PMID: 23885403]
47. Huang XZ, Zhuang JH, Ren YG, Zhou LJ, Zhou Q. [Association of interleukin-6 and interleukin-18 gene polymorphism with rheumatoid arthritis in Guangdong Han population]. Nanfang Yike Daxue Xuebao 2007; 27: 1661-1664 [PMID: 18024284]
48. Lee CC, Lin WY, Wan L, Tsai Y, Lin YJ, Tsai CH, Huang CM, Tsai FJ. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics 2007; 59: 433-439 [PMID: 17396252 DOI: 10.1007/s00251-007-0212-z]
49. Sugiura T, Kawaguchi Y, Ikari K, Ichida H, Kawamoto M, Momohara S, Hara M, Yamanaka H. Interleukin-18 promoter polymorphisms in Japanese patients with rheumatoid arthritis: protective effect of the T allele and T/T genotype at rs360722. Mod Rheumatol 2011; 21: 359-364 [PMID: 21225442 DOI: 10.1007/s10165-010-0399-y]
50. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul WE. Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J Exp Med 1982; 155: 914-923 [PMID: 6977612]
51. Hussein YM, El-Shal AS, Rezk NA, Abdel Galil SM, Alzahrani SS. Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cytokine 2013; 61: 849-855 [PMID: 23394902 DOI: 10.1016/j.cyto.2013.01.001]
52. Pawlik A, Wrzesniewska J, Florczak M, Gawronska-Szklarz B, Herczynska M. The -590 IL-4 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int 2005; 26: 48-51 [PMID: 15660235 DOI: 10.1007/s00296-004-0539-9]
53. Song GG, Bae SC, Kim JH, Lee YH. Interleukin-4, interleukin-4 receptor, and interleukin-18 polymorphisms and rheumatoid arthritis: a meta-analysis. Immunol Invest 2013; 42: 455-469 [PMID: 23883285 DOI: 10.3109/08820139.2013.804084]
54. Burgos PI, Causey ZL, Tamhane A, Kelley JM, Brown EE, Hughes LB, Danila MI, van Everdingen A, Conn DL, Jonas BL, Callahan LF, Smith EA, Brasington RD, Moreland LW, van der Heijde DM, Alarcón GS, Bridges SL. Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. Arthritis Res Ther 2010; 12: R75 [PMID: 20444266 DOI: 10.1186/ar2994]
55. Hussein Y, El-Tarhouny S, Mohamed R, Pasha H, Abul-Saoud A. Association of interleukin-4 receptor gene polymorphisms with rheumatoid arthritis in Egyptian female patients. Joint Bone Spine 2012; 79: 38-42 [PMID: 21497535 DOI: 10.1016/j.jbspin.2011.02.017]
56. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32 [PMID: 11133738]
57. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49 [PMID: 10358752 DOI: 10.1146/annurev.immunol.17.1.19]
58. McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19: 75-79 [PMID: 9509762]
59. Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, Saxne T, de Rooy D, Daha N, van der Linden MP, Stoeken G, van Toorn L, Koeleman B, Tsonaka R, Zhernakoza A, Houwing-Duistermaat JJ, Toes R, Huizinga TW, van der Helm-van Mil A. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis 2012; 71: 1651-1657 [PMID: 22440823 DOI: 10.1136/annrheumdis-2011-200724]
60. Rueda B, López-Nevot MA, González-Gay MA, Balsa A, Pascual-Salcedo D, Garcia A, Gonzalez A, Martin J. Molecular screening and association study of IL15 gene polymorphisms in rheumatoid arthritis. Cytokine 2007; 38: 84-89 [PMID: 17616399 DOI: 10.1016/j.cyto.2007.05.005]
61. Christensen U, Haagerup A, Binderup HG, Vestbo J, Kruse TA, Børglum AD. Family based association analysis of the IL2 and IL15 genes in allergic disorders. Eur J Hum Genet 2006; 14: 227-235 [PMID: 16333313 DOI: 10.1038/sj.ejhg.5201541]
62. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678 [PMID: 17554300 DOI: 10.1038/nature05911]
63. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008; 20: 295-301 [PMID: 18554883 DOI: 10.1016/j.coi.2008.02.004]
64. Knevel R, de Rooy DP, Zhernakova A, Gröndal G, Krabben A, Steinsson K, Wijmenga C, Cavet G, Toes RE, Huizinga TW, Gregersen PK, van der Helm-van Mil AH. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1684-1693 [PMID: 23529819 DOI: 10.1002/art.37938]
65. Daha NA, Kurreeman FA, Marques RB, Stoeken-Rijsbergen G, Verduijn W, Huizinga TW, Toes RE. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1255-1260 [PMID: 19404967 DOI: 10.1002/art.24503]
66. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tîrgoviste C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG. Robust associations of four new chromosome regions from genomewide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-864 [PMID: 17554260 DOI: 10.1038/ng2068]
67. Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, Lefèbvre C, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, Mcgovern D, Palmieri O, Achkar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804 [PMID: 19201773 DOI: 10.1136/gut.2008.166918]
68. Márquez A, Orozco G, Martínez A, Palomino-Morales R, Fernández-Arquero M, Mendoza JL, Taxonera C, Díaz-Rubio M, Gómez-García M, Nieto A, López-Nevot MA, de la Concha EG, Martín J, Urcelay E. Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1968-1975 [PMID: 19471255 DOI: 10.1038/ajg.2009.224]
69. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, James JA, Merrill JT, Lipsky P, Harley JB. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 458-461 [PMID: 17720724 DOI: 10.1136/ard.2007.075424]
70. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, Kane JP, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, Barton A, Saccone NL, Bowcock AM. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041 [PMID: 18369459 DOI: 10.1371/journal.pgen.1000041]
71. Albers HM, Kurreeman FA, Stoeken-Rijsbergen G, Brinkman DM, Kamphuis SS, van Rossum MA, Girschick HJ, Wouters C, Saurenmann RK, Hoppenreijs E, Slagboom P, Houwing-Duistermaat JJ, Verduijn W, Huizinga TW, Ten Cate R, Toes RE, Schilham MW. Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 901-904 [PMID: 19248117 DOI: 10.1002/art.24296]
72. Hollis-Moffatt JE, Chen-Xu M, Topless R, Dalbeth N, Gow PJ, Harrison AA, Highton J, Jones PB, Nissen M, Smith MD, van Rij A, Jones GT, Stamp LK, Merriman TR: Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance. Arthritis Res Ther 2010; 12: R116 [DOI: 10.1186/ar3053]
73. Zdanov A. Structural features of the interleukin-10 family of cytokines. Curr Pharm Des 2004; 10: 3873-3884 [PMID: 15579076 DOI: 10.2174/1381612043382602]
74. Deniz G, Erten G, Kücüksezer UC, Kocacik D, Karagiannidis C, Aktas E, Akdis CA, Akdis M. Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 2008; 180: 850-857 [PMID: 18178824 DOI: 10.4049/jimmunol.180.2.850]
75. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492-5499 [PMID: 7730651]
76. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8 [PMID: 9043871 DOI: 10.1111/j.1365-2370.1997.tb00001.x]
77. Guzowski D, Chandrasekaran A, Gawel C, Palma J, Koenig J, Wang XP, Dosik M, Kaplan M, Chu CC, Chavan S, Furie R, Albesiano E, Chiorazzi N, Goodwin L. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 2005; 16: 154-166 [PMID: 16030322]
78. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mol Biol Rep 2012; 39: 81-87 [PMID: 21553228 DOI: 10.1007/s11033-011-0712-7]
79. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-1450 [PMID: 11685118]
80. Hee CS, Gun SC, Naidu R, Gupta E, Somnath SD, Radhakrishnan AK. Comparison of single nucleotide polymorphisms in the human interleukin-10 gene promoter between rheumatoid arthritis patients and normal subjects in Malaysia. Mod Rheumatol 2007; 17: 429-435 [PMID: 17929139 DOI: 10.1007/s10165-007-0612-9]
81. Pawlik A, Kurzawski M, Szklarz BG, Herczynska M, Drozdzik M. Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis. Clin Rheumatol 2005; 24: 480-484 [PMID: 15915323 DOI: 10.1007/s10067-004-1066-5]
82. Ying B, Shi Y, Pan X, Song X, Huang Z, Niu Q, Cai B, Wang L. Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis. Mol Biol Rep 2011; 38: 379-385 [PMID: 20424918 DOI: 10.1007/s11033-010-0119-x]
83. Zhang J, Zhang Y, Jin J, Li M, Xie K, Wen C, Cheng R, Chen C, Lu J. The -1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: a meta-analysis. Cytokine 2011; 56: 351-355 [PMID: 21764596 DOI: 10.1016/j.cyto.2011.05.022]
84. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722-728 [PMID: 22814351 DOI: 10.1038/ni.2366]
85. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725 [PMID: 11114383]
86. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003; 19: 159-163 [PMID: 12932349]
87. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 2008; 67: 1474-1479 [PMID: 18199596 DOI: 10.1136/ard.2007.083360]
88. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685 [PMID: 17699845 DOI: 10.1158/1078-0432.CCR-07-0776]
89. Villarino AV, Hunter CA. Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 2004; 6: 225-233 [PMID: 15380038 DOI: 10.1186/ar1227]
90. Goriely S, Goldman M. The interleukin-12 family: new players in transplantation immunity? Am J Transplant 2007; 7: 278-284 [PMID: 17229073 DOI: 10.1111/j.1600-6143.2006.01651.x]
91. Goriely S, Goldman M. Interleukin-12 family members and the balance between rejection and tolerance. Curr Opin Organ Transplant 2008; 13: 4-9 [PMID: 18660699 DOI: 10.1097/MOT.0b013e3282f406c400075200-200802000-00003]
92. Pirhonen J, Matikainen S, Julkunen I. Regulation of virusinduced IL-12 and IL-23 expression in human macrophages. J Immunol 2002; 169: 5673-5678 [PMID: 12421946]
93. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708 [PMID: 12023369]
94. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463 [PMID: 17068223 DOI: 10.1126/science.1135245]
95. Murphy CA, Langrish CL, Chen Y, Blumenschein W, Mc-Clanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-1957 [PMID: 14662908 DOI: 10.1084/jem.20030896jem.20030896]
96. Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K, Sipeky C, Maasz A, Radics J, Gyetvai A, Szekanecz Z, Czirjak L, Melegh B: Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008; 67: 248-250 [DOI: 10.1136/ard.2007.072819]
97. Orozco G, Rueda B, Robledo G, García A, Martín J. Investigation of the IL23R gene in a Spanish rheumatoid arthritis cohort. Hum Immunol 2007; 68: 681-684 [PMID: 17678723 DOI: 10.1016/j.humimm.2007.05.008]
98. Chang M, Saiki RK, Cantanese JJ, Lew D, van der Helm-van Mil AH, Toes RE, Huizinga TW, Ardlie KG, Criswell LA, Seldin MF, Amos CI, Kastner DL, Gregersen PK, Schrodi SJ, Begovich AB. The inflammatory disease-associated variants in IL12B and IL23R are not associated with rheumatoid arthritis. Arthritis Rheum 2008; 58: 1877-1881 [PMID: 18512797 DOI: 10.1002/art.23492]
99. Varade J, Ramón Lamas J, Rodríguez L, Fernández-Arquero M, Loza-Santamaría E, Jover JA, de la Concha EG, Fernández-Gutierrez B, Urcelay E, Martínez A. IL23R and IL12B genes: susceptibility analysis in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1230-1232 [PMID: 19525409 DOI: 10.1136/ard.2008.099275]
100. Hollis-Moffatt JE, Merriman ME, Rodger RA, Rowley KA, Chapman PT, Dalbeth N, Gow PJ, Harrison AA, Highton J, Jones PB, O'Donnell JL, Stamp LK, Merriman TR. Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1340-1344 [PMID: 18647855 DOI: 10.1136/ard.2008.090142]
101. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK. TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med 2007; 357: 1199-1209 [PMID: 17804836 DOI: 10.1056/NEJMoa073491]
102. Chen-Xu M, Topless R, McKinney C, Merriman ME, Phipps-Green A, Dalbeth N, Gow PJ, Harrison AA, Highton J, Jones PB, Nissen M, Smith MD, van Rij A, Jones GT, Rodriguez-Rodriguez L, Fernandez-Gutierrez B, Teruel M, Balsa A, Pascual-Salcedo D, Ortiz AM, Gonzalez-Gay MA, Steer S, Maehlen M, Lie B, Wordsworth BP, Stamp LK, Martin J, Merriman TR. Replication of association of the interleukin 23 receptor rs1343151 variant with rheumatoid arthritis in Caucasian sample sets. Ann Rheum Dis 2012; 71: 155-157 [PMID: 21926184 DOI: 10.1136/annrheumdis-2011-200591]
103. Song GG, Bae SC, Choi SJ, Ji JD, Lee YH. Associations between interleukin-23 receptor polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mol Biol Rep 2012; 39: 10655-10663 [PMID: 23053963 DOI: 10.1007/s11033-012-1955-7]
104. Zhai Y, Xu K, Huang F, Peng H, Feng CC, Zhu KK, Leng RX, Pan HF, Ye DQ. Association of interleukin 23 receptor gene polymorphisms (rs10489629, rs7517847) with rheumatoid arthritis in European population: a meta-analysis. Mol Biol Rep 2012; 39: 8987-8994 [PMID: 22718508 DOI: 10.1007/s11033-012-1768-8]
105. Lee YH, Choi SJ, Ji JD, Song GG. Associations between interleukin-23R polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Inflamm Res 2012; 61: 143-149 [PMID: 22089529 DOI: 10.1007/s00011-011-0398-2]
106. Park JH, Kim YJ, Park BL, Bae JS, Shin HD, Bae SC. Lack of association between interleukin 23 receptor gene polymorphisms and rheumatoid arthritis susceptibility. Rheumatol Int 2009; 29: 781-786 [PMID: 19034457 DOI: 10.1007/s00296-008-0770-x]
107. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20 [PMID: 12773095 DOI: 10.1042/BJ20030407]
108. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32: 1443-1452 [PMID: 2554932]
109. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300: 2101-2104 [PMID: 12829785 DOI: 10.1126/science.1083901]
110. Filippucci E, Iagnocco A, Meenagh G, Riente L, Delle Sedie A, Bombardieri S, Valesini G, Grassi W. Ultrasound imaging for the rheumatologist. Clin Exp Rheumatol 2006; 24: 1-5 [PMID: 16539811]
111. Newton JL, Harney SM, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun 2004; 5: 151-157 [PMID: 14749714 DOI: 10.1038/sj.gene.6364045]
112. Kilding R, Iles MM, Timms JM, Worthington J, Wilson AG. Additional genetic susceptibility for rheumatoid arthritis telomeric of the DRB1 locus. Arthritis Rheum 2004; 50: 763-769 [PMID: 15022317 DOI: 10.1002/art.20043]
113. Chang WW, Su H, He L, Zhao KF, Wu JL, Xu ZW: Association between transforming growth factor-beta1 T869C polymorphism and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 2010; 49: 652-656 [DOI: 10.1093/rheumatology/kep417]
114. Marinou I, Healy J, Mewar D, Moore DJ, Dickson MC, Binks MH, Montgomery DS, Walters K, Wilson AG. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007; 56: 2549-2556 [PMID: 17665434 DOI: 10.1002/art.22814]
115. Mattey DL, Nixon N, Dawes PT, Kerr J. Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1190-1194 [PMID: 15695537 DOI: 10.1136/ard.2004.031674]
116. Pascual M, Nieto A, Matarán L, Balsa A, Pascual-Salcedo D, Martín J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1: 338-340 [PMID: 11196696 DOI: 10.1038/sj.gene.6363677]
117. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J, Martin J, Gonzalez-Gay MA. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 964-970 [PMID: 20149313]
118. Lo SF, Huang CM, Lin HC, Chen WC, Tsai CH, Tsai FJ. Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Clin Exp Rheumatol 2008; 26: 632-637 [PMID: 18799095]
119. Zhang S, Zhang P, Huang QY. Association of the D358A polymorphism of IL6R gene with type 2 diabetes in Hubei Han Chinese. Zhonghua Yixue Yichuan Xue Zazhi 2009; 26: 452-456 [PMID: 20017315]
120. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta 2002; 1592: 251-263 [PMID: 12421670]
121. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-236 [PMID: 16707558 DOI: 10.1189/jlb.1105674]
122. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res 2012; 61: 665-671 [PMID: 22427231 DOI: 10.1007/s00011-012-0459-1]
123. Li H, Chen J, Huang A, Stinson J, Heldens S, Foster J, Dowd P, Gurney AL, Wood WI. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000; 97: 773-778 [PMID: 10639155]
124. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, Wang W, Wathen K, Hodge V, Fisher CL, Olsen H, Ruben SM, Knyazev I, Cho YH, Kao V, Wilkinson KA, Carrell JA, Ebner R. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000; 275: 19167-19176 [PMID: 10749887 DOI: 10.1074/jbc.M910228199]
125. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001; 276: 1660-1664 [PMID: 11058597 DOI: 10.1074/jbc.M008289200]
126. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002; 169: 642-646 [PMID: 12097364]
127. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004; 114: 1265-173; quiz 1274 [PMID: 15577820 DOI: 10.1016/j.jaci.2004.10.019]
128. Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150: 5445-5456 [PMID: 8390535]
129. Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J. The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 2007; 55: 329-334 [PMID: 18219763]
130. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001; 20: 5332-5341 [PMID: 11574464 DOI: 10.1093/emboj/20.19.5332]
131. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476 [PMID: 15485625 DOI: 10.1016/j.immuni.2004.08.018]
132. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-174 [PMID: 12651226]
133. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567 [PMID: 19575028 DOI: 10.1038/nri2586]
134. Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, Wojciechowska B, Lacki JK, Maslinski S. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010; 72: 134-141 [PMID: 20618772 DOI: 10.1111/j.1365-3083.2010.02411.x]
135. Nordang GB, Viken MK, Hollis-Moffatt JE, Merriman TR, Førre ØT, Helgetveit K, Kvien TK, Lie BA. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford) 2009; 48: 367-370 [PMID: 19208686 DOI: 10.1093/rheumatology/ken512]
136. Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, Kamatani N, Kotake S. Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. Clin Rheumatol 2007; 26: 2137-2141 [PMID: 17876645 DOI: 10.1007/s10067-007-0745-4]
137. Emonts M, Hazes MJ, Houwing-Duistermaat JJ, van der Gaast-de Jongh CE, de Vogel L, Han HK, Wouters JM, Laman JD, Dolhain RJ. Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study. BMC Med Genet 2011; 12: 36 [PMID: 21385363 DOI: 10.1186/1471-2350-12-36]
138. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of diseasemodifying antirheumatic drugs. Ann Rheum Dis 2014; 73: 3-5 [PMID: 24072562 DOI: 10.1136/annrheumdis-2013-204317]
139. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol 2003; 15: 226-236 [PMID: 12707575]
140. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509 [PMID: 24161836 DOI: 10.1136/annrheumdis-2013-204573]
141. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784 [PMID: 18512708 DOI: 10.1002/art.23721]
142. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-639 [PMID: 22473917 DOI: 10.1002/acr.21641]
143. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735 [PMID: 7779114]
144. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145 [PMID: 7362664]
145. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-581 [PMID: 8478878]
146. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009; 338: b702 [PMID: 19289413]
147. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-450 [PMID: 15188332 DOI: 10.1002/art.20407]
148. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733 [PMID: 9034190 DOI: 10.1038/385729a0]
149. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-952 [PMID: 9551933]
150. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother 2001; 2: 75-84 [PMID: 11336570]
151. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61 Suppl 2: ii70-ii73 [PMID: 12379628]
152. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM, Vaddi K. Biology of TACE inhibition. Ann Rheum Dis 2001; 60 Suppl 3: iii25-iii32 [PMID: 11890648]
153. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706-709 [PMID: 2901567]
154. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-1325 [PMID: 8001745]
155. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204 [PMID: 9870876 DOI: 10.1002/1529-0131(199812)41]
156. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-624 [PMID: 11920396 DOI: 10.1002/art.10141]
157. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009; 11: 81-89 [PMID: 19169963]
158. Svenson M, Nedergaard S, Heegaard PM, Whisenand TD, Arend WP, Bendtzen K. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur J Immunol 1995; 25: 2842-2850 [PMID: 7589081 DOI: 10.1002/eji.1830251020]
159. Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72: 583-589 [PMID: 23144446 DOI: 10.1136/annrheumdis-2012-202470]
160. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71: 1183-1189 [PMID: 22328739 DOI: 10.1136/annrheumdis-2011-200704]
161. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebocontrolled study. Arthritis Rheum 2006; 54: 2807-2816 [PMID: 16947384 DOI: 10.1002/art.22070]
162. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59-68 [PMID: 11781351 DOI: 10.1172/JCI14121]
163. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012; 6: 245-250 [PMID: 23055694 DOI: 10.2147/DDDT.S25426]
164. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570 [PMID: 23348607 DOI: 10.1002/art.37816]
165. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825-1832 [PMID: 11748266 DOI: 10.1172/JCI12097]
166. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173: 145-150 [PMID: 15210768]
167. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104: 282-287 [PMID: 17185418 DOI: 10.1073/pnas.0606854104]
168. Verri WA, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci USA 2008; 105: 2723-2728 [PMID: 18250323 DOI: 10.1073/pnas.0712116105]
169. Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988; 168: 1573-1586 [PMID: 3263464]
170. Schrohenloher RE, Koopman WJ, Woodworth TG, Moreland LW. Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1845-1848 [PMID: 8923354]
171. Brok HP, Tekoppele JM, Hakimi J, Kerwin JA, Nijenhuis EM, De Groot CW, Bontrop RE, 't Hart BA. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collageninduced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001; 124: 134-141 [PMID: 11359452]
172. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuña R, Balsa A, Pascual-Salcedo D, Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol 2003; 21: 639-642 [PMID: 14611115]
173. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, Mc-Innes IB. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52: 2686-2692 [PMID: 16142748 DOI: 10.1002/art.21249]
174. Waldmann TA. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther 2004; 6: 174-177 [PMID: 15225362 DOI: 10.1186/ar1202]
175. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, Dong C, Chen G. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010; 71: 334-341 [PMID: 20079789 DOI: 10.1016/j.humimm.2010.01.010]
176. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC, Collins M. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56: 1152-1163 [PMID: 17393408 DOI: 10.1002/art.22452]
177. Jüngel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, Distler O. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1468-1476 [PMID: 15146416 DOI: 10.1002/art.20218]
178. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 2009; 30: 441-447 [PMID: 19616319 DOI: 10.1016/j.tips.2009.05.006]
179. Wendling D. Interleukin 23: a key cytokine in chronic inflammatory disease. Joint Bone Spine 2008; 75: 517-519 [PMID: 18815066 DOI: 10.1016/j.jbspin.2008.03.004]
180. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 2009; 19: 657-662 [PMID: 19685204 DOI: 10.1007/s10165-009-0217-6]
181. Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY, Min SY, Cho YG, Park KS, Yoon CH, Min JK, Park SH, Sung YC, Kim HY. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008; 181: 1507-1518 [PMID: 18606706]
182. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012; 135: 112-124 [PMID: 22044352 DOI: 10.1111/j.1365-2567.2011.03522.x]
183. Krausz S, Boumans MJ, Gerlag DM, Lufkin J, van Kuijk AW, Bakker A, de Boer M, Lodde BM, Reedquist KA, Jacobson EW, O'Meara M, Tak PP. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1750-1755 [PMID: 22170479 DOI: 10.1002/art.34339]
184. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005; 19: 180-184 [PMID: 15879699]
185. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-970 [PMID: 10323452 DOI: 10.1002/1529-0131(199905)42]
186. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122-1131 [PMID: 16572447 DOI: 10.1002/art.21749]
187. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 929-939 [PMID: 20131262 DOI: 10.1002/art.27334]
188. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72 [PMID: 20926833 DOI: 10.1126/scitranslmed.3001107]
189. van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829-835 [PMID: 8639180]
190. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA, Miossec P. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 1432-1439 [PMID: 7822808]
191. Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, Mizuguchi J, Wada S, Yoshimoto T. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett 2011; 138: 47-53 [PMID: 21453726 DOI: 10.1016/j.imlet.2011.02.022]
192. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666 [PMID: 21576509 DOI: 10.4049/jimmunol.1100315]
193. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184: 7144-7153 [PMID: 20483737 DOI: 10.4049/jimmunol.0902739]
194. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81 [PMID: 11435459 DOI: 10.1172/JCI12466]
195. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C, Gasparini C, Sacre S, Lundberg A, Paleolog E, Horwood NJ, Brennan FM, Foxwell BM. Is NFkappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002; 61 Suppl 2: ii13-ii18 [PMID: 12379614]